NEW YORK (360Dx) – Stemina Biomarker Discovery is developing a metabolomic test to aid in diagnosing autism and identify subtypes of the condition that could inform treatment decisions.

The Madison, Wisconsin-based firm plans to launch the test in early 2018 and will offer it as a laboratory-developed test through its neurological disorders division, NeuroPointDx. The company is currently enrolling at several sites for a 1,500-subject clinical study, the Children's Autism Metabolome Project (CAMP), aimed at validating the test.